Neobe Therapeutics

Startup

Neobe is a preclinical stage biotech company developing a next generation synthetic biology platform to disrupt the solid tumor microenvironment. Our platform is able to program microscopic Trojan horses based on safe strains of tumour colonising bacteria, designed to break down solid tumours and enable therapeutic efficacy. Each product is engineered with proprietary biosensors to be activated only in the tumour microenvironment. Biosensor activation triggers the localised release of stromal remodelling payloads which break down local barriers to infiltration, without affecting healthy tissues. Neobe has two lead programs in triple negative breast cancer and pancreatic adenocarcinoma with demonstrated safety and efficacy in vivo, and are looking to leverage the platform for external biopharma partnerships. 

website